Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory LymphomaJennifer R. Brown, Farrukh T. Awan, Jason Jiang et al.|Clinical Cancer Research|2015Cited by 55
Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and LymphomaJennifer R. Brown, Farrukh T. Awan, Matthew S. Davids et al.|Blood|2011Cited by 11
Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma PatientsJennifer R. Brown, Farrukh T. Awan, Rodrigo Ruiz‐Soto et al.|Blood|2013Cited by 10